Autonomix Medical Gains European Patent for Catheter-Based Tech

Autonomix Medical, a company advancing technologies to revolutionize nervous system disease diagnosis and treatment, was granted a new patent from the European Patent Office titled “Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and/or Development.”

The ‘792 patent (Patent No. 3,226,792) relates to neuromodulation and covers methods and systems use in nerve and receptor monitoring, electrophysiological monitoring, and surgical procedures related to the systems and mechanisms that regulate prostate and tumor growth.

These methods and systems may be used to sense, ablate, and verify neurological traffic to and from the prostate and organs of the lower urinary tract (LUT) to slow, halt, and/or reverse prostate gland or prostate tumor growth. They also have possible uses to address LUT diseases that share physiology of the prostatic plexus, including chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction, by modulating neural activity and hormonal secretions of related organs.

Autonomix Medical said it’s moving plans forward to submit an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) and begin U.S. clinical trials in 2025. This will support a labeling indication to sell the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.

“With the potential to address a wide range of conditions in which nerve activity plays a central role, we remain committed to strengthening our patent portfolio to support future applications and expansion opportunities,” said Autonomix Medical CEO Brad Hauser. “This European patent further validates the broad applicability of our technology across multiple conditions and anatomical targets. While our focus is on advancing development to reduce pancreatic cancer pain by targeting the celiac plexus, we believe our novel approach has the potential to address a broad array of peripheral nerve bundles associated with pain.”

Last month, the company received a U.S. patent that protects its proprietary technology used to collect and process sensing data for real-time physiological monitoring with broad applications in heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring and implant, and robotic and wearable precision applications.